Rentschler Commissions New 2,000L Single-Use Bioreactor

Laupheim, Germany, March 23, 2015 / B3C newswire / -- Rentschler Biotechnologie GmbH, a leading contract manufacturing and development organization (CDMO) for biopharmaceuticals, announced today that their new 2,000L single-use bioreactor has been put into operation.

The new bioreactor, built and commissioned in only six months, doubles Rentschler's single-use manufacturing capabilities. It seamlessly integrates in the existing manufacturing suites by supplementing two already existing 1,000L single-use bioreactors.

With this new bioreactor Rentschler joins the league of only a handful of companies having a 2,000L single-use bioreactor at their disposal, which is today's maximum working volume in single-use.

"The new bioreactor is already very well booked months before its commissioning which proves the high level of confidence customers have in our company," says Frank Ternes, Chief Business Officer at Rentschler. "With this new addition to our facility we strengthen our position in single-use biomanufacturing further and get closer to our goal to manufacture phase III clinical supplies and market supplies completely in single-use."

Rentschler has over five years' experience with single-use bioreactors and features a facility with a completely flexible space concept and movable equipment. Single-use equipment reduces contamination risks and manufacturing costs. It permits a faster product turnaround and a shortened setup time and hence increases the capacity utilization.

Rentschler is also experiencing a high demand for stainless steel manufacturing and will invest €24m to build a Twin system with two 3,000L stainless steel bioreactors.


About Rentschler
Rentschler is a CDMO with over 40 years proven track record in biopharmaceuticals. Focused on the utilization of mammalian cell lines, Rentschler's long experience covers the development and production of recombinant proteins in compliance with international GMP standards. Rentschler's customized solutions range from supporting drug candidate selection, cell line and process development capabilities as well as GMP production to comprehensive analytics and fill & finish. Rentschler's state-of-the-art manufacturing facility includes bioreactors up to 3,000 L and aseptic filling lines for vials (including lyophilization) and prefilled syringes. The long-term experience with international regulatory affairs and authorities complements the offerings. Rentschler's full-service concept allows flexibility on the individual project requirements.


Contact

Dr. Marion Schrader
Senior Director Marketing
Rentschler Biotechnologie GmbH
Tel.: +49 (0) 7392 701 491
[email protected]

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.